APDHX
Price
$19.13
Change
+$0.12 (+0.63%)
Updated
Jan 17 closing price
Net Assets
169.31M
RPEBX
Price
$61.60
Change
+$0.39 (+0.64%)
Updated
Jan 17 closing price
Net Assets
144.81B
Ad is loading...

APDHX vs RPEBX

Header iconAPDHX vs RPEBX Comparison
Open Charts APDHX vs RPEBXBanner chart's image
Artisan Global Equity Advisor
Price$19.13
Change+$0.12 (+0.63%)
VolumeN/A
Net Assets169.31M
American Funds New Perspective R2E
Price$61.60
Change+$0.39 (+0.64%)
VolumeN/A
Net Assets144.81B
APDHX vs RPEBX Comparison Chart
Loading...
View a ticker or compare two or three
VS
APDHX vs. RPEBX commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APDHX is a StrongBuy and RPEBX is a StrongBuy.

Ad is loading...
FUNDAMENTALS
Fundamentals
RPEBX has more cash in the bank: 145B vs. APDHX (169M). APDHX pays higher dividends than RPEBX: APDHX (0.86) vs RPEBX (0.46). APDHX was incepted earlier than RPEBX: APDHX (4 years) vs RPEBX (10 years). APDHX is a more actively managed with annual turnover of: 131.91 vs. RPEBX (17.00). RPEBX has a lower initial minimum investment than APDHX: RPEBX (250) vs APDHX (250000). RPEBX annual gain was more profitable for investors over the last year : 14.72 vs. APDHX (6.61).
APDHXRPEBXAPDHX / RPEBX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence4 years10 years-
Gain YTD-0.0532.037-3%
Front LoadN/AN/A-
Min. Initial Investment250000250100,000%
Min. Initial Investment IRAN/AN/A-
Net Assets169M145B0%
Annual Yield % from dividends0.860.46187%
Returns for 1 year6.6114.7245%
Returns for 3 years3.281.17281%
Returns for 5 yearsN/A29.02-
Returns for 10 yearsN/A71.73-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ACU37.200.62
+1.69%
Acme United Corp
VTOL36.520.17
+0.47%
Bristow Group
OR18.70-0.08
-0.43%
Osisko Gold Royalties Ltd
MANH273.43-2.00
-0.73%
Manhattan Associates
RLMD0.37-0.01
-1.66%
Relmada Therapeutics